Affiliation:
1. Department of Pharmacy, University “G. d’Annunzio” of Chieti-Pescara, Via Dei Vestini, 31, 66100 Chieti, Italy
Abstract
Immunotherapy has marked a revolution in cancer therapy. The most extensively studied target in this field is represented by the protein–protein interaction between PD-1 and its ligand, PD-L1. The promising results obtained with the clinical use of monoclonal antibodies (mAbs) directed against both PD-1 and PD-L1 have prompted the search for small-molecule binders capable of disrupting the protein–protein contact and overcoming the limitations presented by mAbs. The disclosure of the first X-ray complexes of PD-L1 with BMS ligands showed the protein in dimeric form, with the ligand in a symmetrical hydrophobic tunnel. These findings paved the way for the discovery of new ligands. To this end, and to understand the binding mechanism of small molecules to PD-L1 along with the dimerization process, many structure-based computational studies have been applied. In the present review, we examined the most relevant articles presenting computational analyses aimed at elucidating the binding mechanism of PD-L1 with PD-1 and small molecule ligands. Additionally, virtual screening studies that identified validated PD-L1 ligands were included. The relevance of the reported studies highlights the increasingly prominent role that these techniques can play in chemical biology and drug discovery.
Reference101 articles.
1. Inflammation and Cancer: Back to Virchow?;Balkwill;Lancet,2001
2. Coley’s Toxin: Historical Perspective;Bickels;IMAJ Isr. Med. Assoc. J.,2002
3. Immunological Surveillance in Neoplasia;Burnet;Transplant. Rev.,1971
4. Natural Innate and Adaptive Immunity to Cancer;Vesely;Annu. Rev. Immunol.,2011
5. Combination Cancer Immunotherapy and New Immunomodulatory Targets;Mahoney;Nat. Rev. Drug Discov.,2015